



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 75345

Title: Loss of HE Y in HE Y+ breast cancer after neoadjuvant treatment: Case report and literature review

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06254068

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Somalia

Author's Country/Territory: China

Manuscript submission date: 2022-01-25

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-26 10:27

Reviewer performed review: 2022-01-28 17:24

Review time: 2 Days and 6 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input type="checkbox"/>] Anonymous [<input checked="" type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

-The manuscript text is lacking spaces bewtween words and sentences. -Final Conclusion is missing after the discussion -After the abstract, there are paragraphs with no Heading (is INTRODUCTION missing?) -



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 75345

Title: Loss of HE in HE + breast cancer after neoadjuvant treatment: Case report and literature review

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03723209

Position: Editorial Board

Academic degree: FRCS (Ed), FRCS (Gen Surg)

Professional title: Assistant Professor, Doctor

Reviewer's Country/Territory: Singapore

Author's Country/Territory: China

Manuscript submission date: 2022-01-25

Reviewer chosen by: Xin Liu (Online Science Editor)

Reviewer accepted review: 2022-03-08 01:39

Reviewer performed review: 2022-03-08 01:53

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

This is a well written case report describing the loss of Her2 amplification in a patient with breast cancer after neoadjuvant chemotherapy and the authors went on to do a literature review of this phenomenon which has been shown in about 10% of patient in case series. Just a small point i would like the authors to clarify is with regards to the take home message, i think in this patient she continued to complete herceptin even after the her2 loss of amplification, so is the take home message that patient should continue to be treated based on initial her2 status pre neoadjuvant chemotherapy? I believe this point will be useful for readers if it is more explicitly clarified or stated.